{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:05:24Z","timestamp":1789049124125,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Services Incorporation, East Hanover, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML) is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML failing\u2009\u2265\u20092 lines of treatment, partly due to the paucity of head-to-head trials evaluating TKIs. Thus, matching-adjusted indirect comparisons (MAICs) were conducted to compare asciminib with competing TKIs in third- or later line (\u2265\u20093L) CP-CML.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Individual patient-level data for asciminib (ASCEMBL; follow-up:\u2009\u2265\u200948\u00a0weeks) and published aggregate data for comparator TKIs (ponatinib, nilotinib, and dasatinib) informed the analyses. Major molecular response (MMR), complete cytogenetic response (CCyR), and time to treatment discontinuation (TTD) were assessed, where feasible.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Asciminib was associated with statistically significant improvements in MMR by 6 (relative risk [RR]: 1.55; 95% confidence interval [CI]: 1.02, 2.36) and 12\u00a0months (RR: 1.48; 95% CI: 1.03, 2.14) vs ponatinib. For CCyR, the results vs ponatinib were similar by 6 (RR: 1.11; 95% CI: 0.81, 1.52) and 12\u00a0months (RR: 0.97; 95% CI: 0.73, 1.28). Asciminib was associated with improvements in MMR by 6\u00a0months vs dasatinib but with a CI overlapping one (RR 1.52; 95% CI: 0.66, 3.53). Asciminib was associated with statistically significant improvements in CCyR by 6 (RR: 3.57; 95% CI: 1.42, 8.98) and 12\u00a0months (RR: 2.03; 95% CI: 1.12, 3.67) vs nilotinib\/dasatinib. Median TTD was unreached for asciminib in ASCEMBL. However, post-adjustment asciminib implied prolonged TTD vs nilotinib and dasatinib, but not vs ponatinib.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These analyses demonstrate favorable outcomes with asciminib versus competing TKIs, highlighting its therapeutic potential in\u2009\u2265\u20093L CP-CML.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04562-5","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T04:01:52Z","timestamp":1674878512000},"page":"6247-6262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"149","author":[{"given":"Ehab","family":"Atallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Boquimpani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikalp Kumar","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovneet","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"R\u00e9a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"4562_CR1","unstructured":"Acs (2018) Key Statistics for Chronic Myeloid Leukemia.American Cancer Society. <https:\/\/www.cancer.org\/cancer\/chronic-myeloid-leukemia\/about\/statistics.html> 20 Dec, 2021."},{"key":"4562_CR2","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1080\/10428194.2017.1379076","volume":"59","author":"P Boddu","year":"2018","unstructured":"Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J (2018) Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59:1312\u20131322. https:\/\/doi.org\/10.1080\/10428194.2017.1379076","journal-title":"Leuk Lymphoma"},{"key":"4562_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866","volume-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TML (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. University of Leicester, UK"},{"key":"4562_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-137393","volume":"136","author":"TH Br\u00fcmmendorf","year":"2020","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, Le Coutre PD, Garcia-Guti\u00e9rrez V, Chuah C, Kota V, Lipton JH (2020) Bosutinib (BOS) versus imatinib for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML): final 5-year results from the bfore trial. Blood 136:41\u201342","journal-title":"Blood"},{"key":"4562_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"J Cortes","year":"2021","unstructured":"Cortes J, Lang F (2021) Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol 14:44. https:\/\/doi.org\/10.1186\/s13045-021-01055-9","journal-title":"J Hematol Oncol"},{"key":"4562_CR6","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B (2016) Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 34:2333","journal-title":"J Clin Oncol"},{"key":"4562_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ (2013) Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 33:607\u2013617. https:\/\/doi.org\/10.1177\/0272989X12458724","journal-title":"Med Decis Making"},{"key":"4562_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","volume":"9","author":"V Garcia-Gutierrez","year":"2019","unstructured":"Garcia-Gutierrez V, Hernandez-Boluda JC (2019) Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol 9:603. https:\/\/doi.org\/10.3389\/fonc.2019.00603","journal-title":"Front Oncol"},{"key":"4562_CR9","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","volume":"114","author":"RJ Garg","year":"2009","unstructured":"Garg RJ, Kantarjian H, O\u2019brien S, Quintas-Cardama A, Faderl S, Estrov Z, Cortes J (2009) The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 114:4361\u20134368. https:\/\/doi.org\/10.1182\/blood-2009-05-221531","journal-title":"Blood"},{"key":"4562_CR10","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2010.110","volume":"24","author":"FJ Giles","year":"2010","unstructured":"Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GLS, Jagasia M, Mendrek W, Fischer T, Facon T, Dunzinger U, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM (2010) Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 24:1299\u20131301. https:\/\/doi.org\/10.1038\/leu.2010.110","journal-title":"Leukemia"},{"key":"4562_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2210","author":"E Glimm","year":"2022","unstructured":"Glimm E, Yau L (2022) Geometric approaches to assessing the numerical feasibility for conducting matching-adjusted indirect comparisons. Pharm Stat. https:\/\/doi.org\/10.1002\/pst.2210","journal-title":"Pharm Stat"},{"key":"4562_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M, European L (2007) Chronic myeloid leukaemia. Lancet (london, England) 370:342\u2013350. https:\/\/doi.org\/10.1016\/S0140-6736(07)61165-9","journal-title":"Lancet (london, England)"},{"key":"4562_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4161\/cc.10.2.14537","volume":"10","author":"A Hochhaus","year":"2011","unstructured":"Hochhaus A, La Rosee P, Muller MC, Ernst T, Cross NC (2011) Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 10:250\u2013260. https:\/\/doi.org\/10.4161\/cc.10.2.14537","journal-title":"Cell Cycle"},{"key":"4562_CR14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, Le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044\u20131054","journal-title":"Leukemia"},{"key":"4562_CR15","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen J, Hjorth-Hansen H, Richter J, Buske C, Committee EG (2017) Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv41\u2013iv51. https:\/\/doi.org\/10.1093\/annonc\/mdx219","journal-title":"Ann Oncol"},{"key":"4562_CR16","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen J, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saussele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R (2020a) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"4562_CR17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Breccia M, Saglio G, Garcia-Gutierrez V, Rea D, Janssen J, Apperley J (2020b) Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia 34:1495\u20131502. https:\/\/doi.org\/10.1038\/s41375-020-0842-9","journal-title":"Leukemia"},{"key":"4562_CR18","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1182\/blood.V124.21.3145.3145","volume":"124","author":"VS Hoffmann","year":"2014","unstructured":"Hoffmann VS, Lindoerfer D, Thaler J, Boris L, Melanthiou F, Mayer J, Everaus H, Guilhot J, Schubert-Fritschle G, Castagnetti F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Indrak K, Zupan I, Steegmann JL, Simonsson B, Clark R, Hoglund M, Hehlmann R, Hasford J, Baccarani M (2014) Incidence of CML in Europe \u2013 a comparison of 19 European countries with US SEER data. Blood 124:3145","journal-title":"Blood"},{"key":"4562_CR19","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1182\/blood-2010-06-291922","volume":"116","author":"AR Ibrahim","year":"2010","unstructured":"Ibrahim AR, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad JS, Foroni L, Reid A, De Lavallade H, Rezvani K, Dazzi F, Apperley JF, Goldman JM, Marin D (2010) Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood 116:5497\u20135500. https:\/\/doi.org\/10.1182\/blood-2010-06-291922","journal-title":"Blood"},{"key":"4562_CR20","doi-asserted-by":"publisher","first-page":"A695","DOI":"10.1016\/j.jval.2017.08.1785","volume":"20","author":"C Ivanescu","year":"2017","unstructured":"Ivanescu C, Skaltasa K, Kr\u00e1\u013e P (2017) Acceptance of population-adjusted indirect treatment comparison methods in nice assessments. Value in Health 20:A695. https:\/\/doi.org\/10.1016\/j.jval.2017.08.1785","journal-title":"Value in Health"},{"key":"4562_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H (2016) Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 91:252\u2013265. https:\/\/doi.org\/10.1002\/ajh.24275","journal-title":"Am J Hematol"},{"key":"4562_CR22","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H (2020) Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 95:691\u2013709. https:\/\/doi.org\/10.1002\/ajh.25792","journal-title":"Am J Hematol"},{"key":"4562_CR23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","volume":"82","author":"HM Kantarjian","year":"1993","unstructured":"Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M (1993) Chronic myelogenous leukemia: a concise update. Blood 82:691\u2013703","journal-title":"Blood"},{"key":"4562_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, Le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE (2021) Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 35:440\u2013453","journal-title":"Leukemia"},{"key":"4562_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/03007995.2018.1510225","volume":"35","author":"MY Levy","year":"2019","unstructured":"Levy MY, Mcgarry LJ, Huang H, Lustgarten S, Chiroli S, Iannazzo S (2019) Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison. Curr Med Res Opin 35:479\u2013487. https:\/\/doi.org\/10.1080\/03007995.2018.1510225","journal-title":"Curr Med Res Opin"},{"key":"4562_CR26","doi-asserted-by":"publisher","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW (2020) The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 98:106458. https:\/\/doi.org\/10.1016\/j.leukres.2020.106458","journal-title":"Leuk Res."},{"key":"4562_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1182\/hematology.2021000239","volume":"2021","author":"MJ Mauro","year":"2021","unstructured":"Mauro MJ (2021) Lifelong TKI therapy: how to manage cardiovascular and other risks. Hematology Am Soc Hematol Educ Program 2021:113\u2013121. https:\/\/doi.org\/10.1182\/hematology.2021000239","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"4562_CR28","unstructured":"NCCN (2021) Clinical Practice Guidelines in Oncology - Chronic Myeloid Leukemia (Version 3.2021 - January 13, 2021).National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf 20 Dec, 2021."},{"key":"4562_CR29","unstructured":"Nice (2022) Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]."},{"key":"4562_CR30","unstructured":"Novartis (2021) FDA approves Novartis Scemblix\u00ae (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia.https:\/\/www.novartis.com\/news\/media-releases\/fda-approves-novartis-scemblix-asciminib-novel-mechanism-action-treatment-chronic-myeloid-leukemia 20 Dec, 2021."},{"key":"4562_CR31","unstructured":"Novartis (2022) Novartis receives positive CHMP opinion for Scemblix\u00ae, a novel treatment for adult patients with chronic myeloid leukemia.https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-positive-chmp-opinion-scemblix-novel-treatment-adult-patients-chronic-myeloid-leukemia 12 Sept, 2022."},{"key":"4562_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ (2018) Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making 38:200\u2013211. https:\/\/doi.org\/10.1177\/0272989X17725740","journal-title":"Med Decis Making"},{"key":"4562_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1017\/S0266462319000333","volume":"35","author":"DM Phillippo","year":"2019","unstructured":"Phillippo DM, Dias S, Elsada A, Ades AE, Welton NJ (2019) Population Adjustment Methods for Indirect Comparisons: A Review of National Institute for Health and Care Excellence Technology Appraisals. Int J Technol Assess Health Care 35:221\u2013228. https:\/\/doi.org\/10.1017\/S0266462319000333","journal-title":"Int J Technol Assess Health Care"},{"key":"4562_CR34","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR & Welton NJ (2016) NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. Report by the Decision Support Unit"},{"key":"4562_CR35","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D Rea","year":"2021","unstructured":"Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, Le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garcia-Gutierrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bedoucha V, Hochhaus A (2021) A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138:2031\u20132041. https:\/\/doi.org\/10.1182\/blood.2020009984","journal-title":"Blood"},{"key":"4562_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.6061\/clinics\/2015(08)04","volume":"70","author":"BF Ribeiro","year":"2015","unstructured":"Ribeiro BF, Miranda EC, Albuquerque DM, Delamain MT, Oliveira-Duarte G, Almeida MH, Vergilio B, Silveira RA, Oliveira-Duarte V, Lorand-Metze I, De Souza CA, Pagnano KB (2015) Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors\u2013a single center experience. Clinics (sao Paulo) 70:550\u2013555. https:\/\/doi.org\/10.6061\/clinics\/2015(08)04","journal-title":"Clinics (sao Paulo)"},{"key":"4562_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-3-319-64263-5_2","volume-title":"Neoplastic diseases of the blood","author":"M Rohrbacher","year":"2018","unstructured":"Rohrbacher M, Hasford J (2018) Epidemiology and etiology of chronic myeloid leukemia. Neoplastic diseases of the blood. Springer, Cham, pp 9\u201317"},{"key":"4562_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3324\/haematol.2012.064337","volume":"98","author":"AR Rossi","year":"2013","unstructured":"Rossi AR, Breccia M, Abruzzese E, Castagnetti F, Luciano L, Gozzini A, Annunziata M, Martino B, Stagno F, Cavazzini F, Tiribelli M, Visani G, Pregno P, Musto P, Fava C, Sgherza N, Albano F, Rosti G, Alimena G, Specchia G (2013) Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica 98:399\u2013403. https:\/\/doi.org\/10.3324\/haematol.2012.064337","journal-title":"Haematologica"},{"key":"4562_CR39","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE (2015) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2:e186-193. https:\/\/doi.org\/10.1016\/S2352-3026(15)00048-4","journal-title":"Lancet Haematol"},{"key":"4562_CR40","unstructured":"Seer (2021) Cancer Stat Facts: Leukemia-Chronic Myeloid Leukemia (CML) [Internet]. National Cancer Institute Surveillance Epidemiology, and End Results Program.SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html. 20 Dec, 2021."},{"key":"4562_CR41","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao YJ, Gupta SR, Mulani PM (2010) Comparative effectiveness without head-to-head trials a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 28:935\u2013945. https:\/\/doi.org\/10.2165\/11538370-000000000-00000","journal-title":"Pharmacoeconomics"},{"key":"4562_CR42","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ (2012) Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15:940\u2013947. https:\/\/doi.org\/10.1016\/j.jval.2012.05.004","journal-title":"Value Health"},{"key":"4562_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000495335","volume":"142","author":"J Tan","year":"2019","unstructured":"Tan J, Xue M, Pan J, Cen J, Qi X, Liu P, Zhao X, Wu P, Wang Q, Liu D, Liu Y, Chen S, Wang Z (2019) Responses to dasatinib as a second- and third-line tyrosine kinase inhibitor in chronic phase chronic myeloid leukaemia patients. Acta Haematol 142:79\u201386. https:\/\/doi.org\/10.1159\/000495335","journal-title":"Acta Haematol"},{"key":"4562_CR44","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross DM, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen NJ, Sellers WR (2017) The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543:733\u2013737. https:\/\/doi.org\/10.1038\/nature21702","journal-title":"Nature"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04562-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04562-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04562-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T12:18:54Z","timestamp":1689769134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04562-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4562"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04562-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EA reports receiving consulting fees from Novartis, Bristol Myers Squibb, Takeda, and AbbVie. MM reports receiving consulting fees from Bristol Myers Squibb, Takeda, and Pfizer. AH reports receiving consulting fees from Novartis, Bristol Myers Squibb, Pfizer, and Incyte. CB serves on the speakers bureau of Novartis, Jansen, and Pint Pharma; on the board of directors or advisory committees of Novartis and Jansen. YM reports receiving honoraria from Novartis, BMS, Pfizer, and Astellas. LS is an employee of Novartis Healthcare Pvt. Ltd. RC was an employee of Novartis Services Inc. at the time of development of this manuscript. VM was an employee of Novartis Healthcare Pvt. Ltd. at the time of development of this manuscript. DR reports receiving honoraria from Novartis, Incyte, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}